Yingmei Tu

Central US Merck & Co., Inc. - Kenilworth / United States

Medical and Health Sciences / Neurology

AD Scientific Index ID: 5413107

-

Registration, Add Profile,
Premium Membership

Print Your Certificate

Yingmei Tu's MOST POPULAR ARTICLES

1-) Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged≥ 50 years: a …JY Song, CJ Chang, C Andrews, J Diez-Domingo, M Oh, R Dagan, ...Vaccine 39 (43), 6422-6436, 2021342021

2-) Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in menAR Giuliano, T Wilkin, OM Bautista, K Cheon, L Connor, S Dubey, ...Contemporary clinical trials 115, 106592, 2022

3-) Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertensionJR Zhu, NL Sun, K Yang, J Hu, G Xu, H Hong, R Wang, YM Tu, S Ritter, ...Hypertension Research 35 (1), 28-33, 2012

4-) Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapyJ Huang, NL Sun, YM Hao, JR Zhu, Y Tu, V Curt, Y Zhang, ...Clinical and Experimental Hypertension 33 (3), 179-186, 2011212011

5-) V114-016 (PNEU-PATH) study group. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in …JY Song, CJ Chang, C Andrews, J Diez-Domingo, MD Oh, R Dagan, ...Vaccine 39 (43), 6422-6436, 202192021

ARTICLES

Add your articles